---
title: >-
  Use of advanced systemic therapy in adolescent patients with moderate to
  severe atopic dermatitis in the TARGET DERM Registry.
description: >-
  Explore this publication on real-world evidence: Use of advanced systemic
  therapy in adolescent patients with moderate to severe atopic dermatitis in
  the…
date: '2023-01-01'
category: Publications
tags:
  - Care
  - Atopic Dermatitis (AD)
  - Oral Presentation
  - R&D
  - RAD Conference
  - Dermatology
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/care/use-of-advanced-systemic-therapy-in-adolescent-patients/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: use-of-advanced-systemic-therapy-in-adolescent-patients
id: 2a3iPqg9UE4cJXlQOcfKUV
contentType: article
---

## Challenge

Adolescent patients with moderate-to-severe AD represent a high-need subgroup, but real-world data on what proportion of eligible adolescents receive advanced systemic therapy and what characteristics predict AST initiation—versus remaining undertreated—were limited, hindering pediatric AD drug development and label extension planning.

## Solution

The TARGET-DERM AD registry was analyzed to compare demographics, disease severity, and clinical characteristics between AST-treated and AST-naïve adolescents (ages 12–17) with moderate-to-severe disease, identifying predictors of AST initiation using logistic regression.

## Impact

Establishing that more than half of eligible adolescents remain AST-naïve despite severe disease creates the evidence base for pediatric prescriber education and supports regulatory and commercial strategy for adolescent label extensions of AD biologics and JAK inhibitors.

### [Keith D. Knapp](/people/keith-knapp/)

### [Breda Munoz](/people/breda-munoz/)

![Breda Munoz, PhD — Profile Photo](https://images.ctfassets.net/h4s3ip99qawo/3H1T2mfvSNFj6w9tulnreq/a74ae05fe53e400f176d4e9c617b8fb8/breda-munoz.jpg)